Ultimovacs ASA (ULTI) — Cash Flow-to-Debt Ratio
Ultimovacs ASA (ULTI) has a Cash Flow-to-Debt Ratio of -0.74x as of December 2024, meaning its operating cash flow of Nkr-24.70 Million could theoretically repay -1% of its total liabilities (Nkr33.19 Million) in one year. See ULTI working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ultimovacs ASA Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Ultimovacs ASA across 9 annual periods. Also explore Ultimovacs ASA equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ultimovacs ASA (2016–2024)
Year-by-year debt coverage analysis for Ultimovacs ASA. For market capitalisation and broader financial context, see how much is Ultimovacs ASA worth.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.92x | Nkr-163.40 Million | Nkr33.19 Million | ▼ -80.6% |
| 2023 | -2.73x | Nkr-189.83 Million | Nkr69.65 Million | ▲ +2.0% |
| 2022 | -2.78x | Nkr-167.69 Million | Nkr60.32 Million | ▼ -37.8% |
| 2021 | -2.02x | Nkr-125.83 Million | Nkr62.38 Million | ▲ +23.0% |
| 2020 | -2.62x | Nkr-108.22 Million | Nkr41.34 Million | ▼ -38.9% |
| 2019 | -1.89x | Nkr-62.99 Million | Nkr33.41 Million | ▼ -12.1% |
| 2018 | -1.68x | Nkr-50.39 Million | Nkr29.96 Million | ▲ +23.7% |
| 2017 | -2.21x | Nkr-27.23 Million | Nkr12.35 Million | ▲ +51.7% |
| 2016 | -4.57x | Nkr-31.10 Million | Nkr6.81 Million | — |